Medication info

Glyian Duo Tablet 5/850 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin Amorphous›5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
International Pharmaceutical Co., Ltd.
Appearance
Yellowish white, double convex, oval film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP x 5)]
Approval status
Active

MFDS item code 202201390 · Approved 2022.04.04

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The recommended dose of this drug is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose of 10 mg) and the patient's current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this drug from combination therapy with empagliflozin (total daily dose of 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this drug is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Interactions under Precautions for Use). This drug should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this drug, take it as soon as you remember. However, do not take a double dose at one time; if this happens, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is required for patients with mild renal impairment. Because this drug contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this drug is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see section 3. Patients Requiring Caution, item 1 under Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately (see section 2. Patients Who Must Not Take This Drug, item 2 under Precautions for Use). Elderly Patients For patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
International Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Poor blood sugar control in type 2 diabetes
  • cardiovascular disease
View approved original text

This medication helps control blood sugar in adult patients with type 2 diabetes by combining empagliflozin and metformin. When used along with dietary and exercise therapies, it can effectively manage blood sugar levels. It should be administered cautiously to patients with cardiovascular disease. This medication supports health management by improving blood sugar control due to diabetes.

How to take

Adult dose

The recommended dose of this drug is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose of 10 mg) and the patient's current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this drug from combination therapy with empagliflozin (total daily dose of 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this drug is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Interactions under Precautions for Use). This drug should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this drug, take it as soon as you remember. However, do not take a double dose at one time; if this happens, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is required for patients with mild renal impairment. Because this drug contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this drug is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see section 3. Patients Requiring Caution, item 1 under Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately (see section 2. Patients Who Must Not Take This Drug, item 2 under Precautions for Use). Elderly Patients For patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication helps regulate blood sugar. However, it can cause a serious condition known as severe lactic acidosis, so individuals with poor kidney function or heart disease should not use it. Additionally, those allergic to the ingredients in this medication should avoid administration. Dosage should be stopped in cases of acute infection, dehydration, severe heart failure, and prior to certain tests or surgeries. Pregnant or breastfeeding women should also avoid using this medication. Regular monitoring of kidney function is required during treatment, especially for the elderly or those with reduced kidney function. When used with other diabetes medications or insulin, dose adjustments may be necessary due to the risk of hypoglycemia, per physician's instructions. This medication may increase the risk of urinary and genital infections, so any symptoms of infection should prompt immediate consultation with healthcare professionals. Moreover, it can lead to fluid loss or dehydration, making adequate fluid intake vital. Because it may lower vitamin B12 levels, regular blood testing might be necessary. Excessive alcohol consumption should be avoided during treatment, and any unusual symptoms or discomfort after taking the medication should be discussed with a doctor immediately. Especially if pain, swelling, or fever occurs around the perineum, prompt treatment is required to address potential severe infections. Elderly patients or those with decreased kidney function should exercise extra caution, and regular health status checks are essential. Lastly, patients should not arbitrarily stop or adjust dosages of this medication and must follow their doctor's instructions.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is between 1 and 30 degrees Celsius to maintain the effectiveness of the drug and prevent deterioration.

Appearance and packaging

Appearance

Yellowish white, double convex, oval film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP x 5)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.